Results 131 to 140 of about 2,965,220 (293)

Structural insights into complement regulation

, 2018
As an important tool of the innate immune system, the complement system rapidly recognizes and clears invading microbes and host debris. Furthermore, it stimulates B- and T-cell development through cross talks with the adaptive immune system.
Sub Crystal and Structural Chemistry, Crystal and Structural Chemistry, Xue, X., Gros, Piet   +3 more
core  

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Usefulness and analytical performances of complement multiplex assay for measuring complement biomarkers in plasma

International audienceIntroduction. The complement system is involved in numerous diseases, through diverse mechanisms and degree of activation. With the emergence of complement targeting therapeutic, simple and accessible tools to evaluate the extent of
Courbebaisse, Marie, Duval, Anna, Vieira-Martins, Paula, Chauvet, Sophie, Grunenwald, Anne, Peliconi, Julie, Frémeaux-Bacchi, Véronique, Dragon-Durey, Marie-Agnès, Meuleman, Marie-Sophie, Friedlander, Gérard, Revel, Margot, Rezola Artero, Mikel, Dermani, Mohamed, Roumenina, Lubka, Parfait, Béatrice, Lebeaux, David   +15 more
core   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Complement Regulation on Vascular Endothelial Cells—Insights into the Pathogenesis of Thrombotic Microangiopathy [PDF]

, 2015
Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) that occurs due to defective regulation of the alternative complement pathway (AP).
Noone, Damien
core   +1 more source

Spatial heterogeneity of hotspot mutations and clonal relatedness in ovarian endometrioid carcinoma

Molecular Oncology, EarlyView.
Spatially resolved analysis revealed heterogeneous distributions of selected cancer‐associated mutations within ovarian endometrioid carcinomas. Shared mutations between paired endometrial and ovarian tumors supported clonal relatedness. These findings highlight the value of sampling multiple tumor regions when interpreting molecular profiles ...
Takahito Ashihara, Kosuke Murakami, Shiro Takamatsu, Akiko Kanto, Seiichi Mori, Tomoyuki Otani, Kazuko Sakai, Yasushi Kotani, Kazuto Nishio, Kaoru Abiko, Noriomi Matsumura   +10 more
wiley   +1 more source

The multifaceted roles of lysosomes in cancer

Molecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

Molecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau, Daniel Pincher, Clifford Young, Nicholas Chappell, Noor A. Lokman, Parul Mittal, Leigh Donnellan, Martin K. Oehler, Doug A. Brooks, Peter Hoffmann   +9 more
wiley   +1 more source